U.S. purchases another 100K doses of Lilly COVID-19 antibodies

By The Science Advisory Board staff writers

February 26, 2021 -- The U.S. government is purchasing a minimum of 100,000 doses of Eli Lilly's bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1,400 mg together, which are neutralizing antibodies that can treat mild to moderate COVID-19 in patients who are at high risk of progressing to a severe stage.

The government will pay Lilly $210 million and doses will be delivered through March 31. The government also has the option to purchase up to an additional 1.1 million doses through November 25 under the same terms as the base agreement.

The purchase agreement is on top of the U.S. government's commitment to buy a total of 1.45 million doses of bamlanivimab alone -- 1 million of which have already been delivered and the remaining 450,000 doses to follow suit by the end of March.

The neutralizing antibodies will be provided at no out-of-pocket cost to patients, but healthcare facilities may charge a fee for the product's administration, Lilly said.

Copyright © 2021 scienceboard.net

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.